Bifogade filer
Automation of AroCell’s TK 210 ELISA in China
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
AroCell today announced the signing of an additional agreement with ZECEN Biotech for the development of the company's third tumor marker product, TK 210 ELISA, which will be included on ZECEN Biotech's automated platforms. This partnership marks a major milestone for AroCell as we continue to expand our product offerings and improve cancer diagnostics.
AroCell has been collaborating with ZECEN Biotech since 2019 for the development of TPS CLIA on ZECEN Biotech and Fosun's automated CLIA platforms, which are now available on the Chinese market. There is also an ongoing collaboration for the automatization of UBC that started earlier this year. The addition of a third marker, TK1, to automated platforms is consistent with AroCell’s strategy to make its biomarkers available to a larger patient population and further strengthen AroCell’s presence in the Chinese market.
"The company's strategy is to include our tumor markers on automated platforms. We are very happy to start another development project with ZECEN Biotech to include the tumor marker TK1 on their fully automated CLIA system," says Paola Pellegrini, Product Manager at AroCell.
"We believe that including TK1 on ZECEN Biotech's automated platforms will help us achieve our goal of improving cancer diagnostics," says Anders Hultman, CEO of AroCell. He added, "Automating tumor markers reduces the risk of human error and increases the efficiency of the diagnostic process, enabling healthcare professionals to diagnose cancer faster and more accurately. Introducing TK1 on automated platforms in China is a major step forward for AroCell.”
About ZECEN Biotech
ZECEN Biotech Co., Ltd., is a Chinese company that mainly specializes in providing complete solutions for chemiluminescence immunoassay by developing, manufacturing, and marketing CLIA instruments and reagents. The company has research and development centers and a production base in Beijing, Shandong, and Jiangsu. ZECEN Biotech Co., Ltd., and cooperates with leading hospitals in China.